Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 25;38(6):814–828. doi: 10.1002/jbmr.4809

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 5 — Anti‐LRP6/DKK1 combination strategy provided superior protection against 5TGM1‐induced bone loss and vertebral bone strength compared to single treatment. (A) 3D representative images of femurs from naïve or 5TGM1‐bearing mice treated with either anti‐LRP6 Ab alone, anti‐LRP6/DKK1 Ab combination, or their respective isotypes for 21 days. (B) μCT‐derived (i) trabecular bone volume fraction (BV/TV, %), (ii) trabecular thickness (Tb.Th, mm), and (iii) trabecular number (Tb.N, N/mm) in the distal femoral metaphysis in all respective treatment groups at day 21. (C) μCT‐derived (i) trabecular BV/TV (%), (ii) Tb.Th (mm), and (iii) Tb.N (N/mm) in lumbar L₄ vertebrae from each respective treatment groups at day 21. (D) Maximum load to failure (Max Load, N) of L₄ lumbar vertebrae from each respective treatment group. Results plotted as mean ± SD. Ab = antibody; BM = bone marrow; CB = cortical bone; GP = growth plate; i.v. = intravenous; s.c. = subcutaneous; TB = trabecular bone.